Dupixent is a core blockbuster drug co-developed and commercialized by Sanofi (SNY) and Regeneron (REGN). Although pediatric CSU is just one sub-indication, the approval or rejection of new indications directly affects the drug's revenue ceiling and is capable of causing tradable volatility in the stock prices of these two pharmaceutical giants.

From April 21, 2026 to April 22, 2026, the price of Option_'Yes' surged from 46.5c to a peak of 83c, before slightly pulling back to 78.5c. This is likely due to increased market anticipation of an approval as the PDUFA date (April 27) approaches, or possibly driven by favorable insider information or positive analyst reports. Prior to this, no historical movement records were available. The price had been relatively stable at 46.5c over the past three days, reflecting an early wait-and-see attitude.

This is a prediction about the future valuation of a specific DeFi or crypto project (Pacifica). It is a standard topic for crypto insiders but a niche market for the general public. The obscurity of Pacifica as a specific project makes it moderately exotic.

This is a prediction about the career move of a specific executive/key employee (Ari Weinstein). While not as widely watched as an OpenAI CEO departure, as a known figure in tech (Workflow co-founder), it falls under niche industry gossip or personnel changes—neither common knowledge nor completely absurd.

This event directly tracks the domestic opening weekend box office performance of the movie 'Michael'. Lionsgate (LGF.A) is handling its North American distribution. As a relatively smaller studio, a significant beat or miss on the opening weekend for this major biopic tentpole could cause a notable tradable movement in its stock (around 5% or more). Comcast (CMCSA), whose Universal Pictures handles international distribution, is included due to overall franchise association, but would see negligible impact given its massive market cap and the market's strict focus on domestic figures.

April 20, 2026 - April 22, 2026, the price of the 70-75m option dropped from 14.25c to around 6c, while the >80m option rebounded from 71.5c to 81.5c. This occurred as more real-time presale and showtime data emerged closer to release, causing the market to discard lower-end estimates and heavily concentrate funds back into the highly optimistic $80M+ range. April 21, 2026 - April 22, 2026, the >80m option fluctuated wildly between 69.5c and 79.5c, as the market struggled to reconcile authoritative downward projections ($65-$70M by Deadline/Variety) with earlier highly optimistic long-range forecasts of $80M+. April 20, 2026 - April 22, 2026, the price of the >80m option retreated from a peak of 80.5c to around 70.5c, as some agencies slightly adjusted their tracking data, reducing the likelihood of extreme high-end projections. April 18, 2026 - April 19, 2026, the price of the >80m option surged from 56.5c to 79c. This was due to highly optimistic opening weekend box office tracking projections of $80M-$90M released by Box Office Pro and Box Office Theory, which significantly boosted market confidence.

There is a significant divergence between the prediction market and traditional mainstream media/industry tracking. According to recent context, mainstream outlets like Deadline and Variety downgraded their box office projections to $65M-$70M due to poor early critical reception. However, capital allocation in the prediction market tells a completely different story, currently assigning a massive 79% implied probability to the '>80m' option. This indicates that traders believe traditional tracking models are failing to capture the biopic's deep reach among core fanbases and expected massive walk-up sales.